Eli Lilly has officially initiated clinical trials for its oral weight-loss drug, Orforglipron, in the United Kingdom. This marks a significant shift from the company’s current flagship injectable treatments, Mounjaro and Zepbound, moving the pharmaceutical giant into the highly anticipated market for once-daily pills.
The move comes as Lilly attempts to capture a wider patient base—those hesitant to use needles. While injectable GLP-1 agonists have dominated headlines, the logistical hurdles of cold-chain storage and self-injection remain barriers for many. Orforglipron bypasses these entirely. It’s a non-peptide molecule, meaning it doesn’t require the same delicate handling as injectable biologics.
Industry analysts are watching the UK rollout closely. If the oral drug mirrors the efficacy of its injectable counterparts, it could disrupt the weight-loss market. Patients currently face significant supply chain delays for Mounjaro; a pill, which is easier to manufacture and distribute, could alleviate some of that pressure.
However, the medical community remains cautious. Dr. Sarah Jenkins, a clinical endocrinologist, points to the “compliance factor.”
“Daily adherence is a different beast than a weekly injection,” she said. “Patients often find it easier to remember one shot a week than to maintain a strict daily pill regimen, especially when side effects like nausea kick in.”
Lilly is positioning the drug not just as an alternative, but as a long-term strategy to scale production. Scaling the manufacturing of peptides is notoriously difficult and expensive. Synthesizing a small-molecule drug like Orforglipron, however, is a standard process for major pharmaceutical plants.
The UK trials will provide the data necessary for the Medicines and Healthcare products Regulatory Agency (MHRA) to evaluate long-term safety. If approved, the drug would represent the first of a new generation of oral GLP-1 treatments to hit the British market.
For now, the focus is on the data. Lilly needs to prove that the pill offers enough weight reduction to compete with the high-performing injectables already setting the standard. Whether patients prioritize the convenience of a pill over the proven results of a weekly injection remains the central question for the industry.
